Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE.

Neurology. 2006 Jun 27;66(12):1941-3.

PMID:
16801668
2.

Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.

Valkovic P, Benetin J, Blazícek P, Valkovicová L, Gmitterová K, Kukumberg P.

Parkinsonism Relat Disord. 2005 Jun;11(4):253-6. Epub 2005 Apr 20.

PMID:
15878587
3.

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

Di Rocco A, Werner P.

Neurology. 2007 Apr 24;68(17):1440; author reply 1440-1. No abstract available.

PMID:
17452598
4.

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA.

Clin Neuropharmacol. 2006 May-Jun;29(3):106-11. Review.

PMID:
16772808
5.

Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.

Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R.

Arch Neurol. 2003 Jan;60(1):59-64.

PMID:
12533089
6.

Homocysteine in restless legs syndrome.

Bachmann CG, Guth N, Helmschmied K, Armstrong VW, Paulus W, Happe S.

Sleep Med. 2008 May;9(4):388-92. Epub 2007 Sep 27.

PMID:
17900981
7.

Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.

O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R.

Mov Disord. 2004 Dec;19(12):1403-8.

PMID:
15390053
8.
9.

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, Livrea P.

Mov Disord. 2005 Jan;20(1):69-72.

PMID:
15390046
10.

Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.

Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA.

Neurology. 2003 Apr 8;60(7):1125-9.

PMID:
12682318
11.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
12.

Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.

Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P.

Parkinsonism Relat Disord. 2009 Jul;15(6):477-8. doi: 10.1016/j.parkreldis.2008.10.005. Epub 2008 Nov 22. No abstract available.

PMID:
19028438
13.

The effect of entacapone on homocysteine levels in Parkinson disease.

Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, Bronstein J.

Neurology. 2005 Apr 26;64(8):1482. No abstract available.

PMID:
15851757
14.

[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.

Neurologia. 2005 May;20(4):180-8. Review. Spanish.

PMID:
15891947
15.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
16.

[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].

Zhao P, Yang JF, Liu W, Wang Y, Sun YN, Li Q, Zhang W, Zhang BS.

Zhonghua Yi Xue Za Zhi. 2013 Feb 19;93(7):512-5. Chinese.

PMID:
23660319
17.

Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?

Postuma RB, Lang AE.

Neurology. 2004 Sep 14;63(5):886-91. Review.

PMID:
15365141
18.

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.

Mov Disord. 1997 Jul;12(4):497-505.

PMID:
9251066
19.

Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?

Kocer B, Guven H, Comoglu SS.

Biomed Res Int. 2016;2016:7563705. doi: 10.1155/2016/7563705. Epub 2016 Jul 17.

20.

Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.

Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, Iliceto G, Livrea P.

Eur J Neurol. 2005 May;12(5):365-8.

PMID:
15804266

Supplemental Content

Support Center